Skip to main content

Table 1 Demographic and Clinical Characteristics at Baseline

From: Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients

Patient characteristics Study group, n = 30 Control group, n = 30 P
Gender (male), n (%) 21 (70) 19 (63.3) 0.58
Age (years) (mean) 58.17 ± 11.52 66.23 ± 13.31 0.15
Comorbid conditions, n (%)
 Diabetes mellitus 9 (30) 10 (33.3) 0.78
 Hypertension 15 (50) 12 (40) 0.43
 Coronary artery disease 5 (16.7) 8 (26.7) 0.34
 Cardiac failure 1 (3.3) 0.31
 Chronic Obstructive Pulmonary Disease 6 (20) 3 (10) 0.27
 Malignancy 1 (3.3) 0.36
 Immunodeficiency 1 (3.3) 0.31
Symptoms, n (%)
 Fever 15 (59) 13 (43.3) 0.60
 Cough 16 (53.3) 14 (46.7) 0.60
 Sore throat 3 (10) 1 (3.3) 0.30
 Dyspnea 23 (76.7) 19 (63.3) 0.26
 Headache 5 (16.7) 2 (6.7) 0.22
 Weakness 13 (43.3) 11 (3.7) 0.59
 Myalgia 9 (30) 7 (23.3) 0.55
 Diarrhea 1 (3.3) 0.31
 Nausea or vomiting 1 (3.3) 0.31
Signs (mean)
 Body temperature (0C) 36.9 ± 0.7 36.8 ± 0.8 0.15
 Heart rate (per minute) 88 ± 12 92 ± 18 0.47
 Respiratory rate (per minute) 24 ± 5 24.7 ± 0.7 0.92
 Systolic pressure (mmHg) 124.39 ± 15.60 124.61 ± 15.37 0.85
 Diastolic pressure (mmHg) 75.64 ± 9.79 73.43 ± 8.47 0.07
 Inspiratory ral, n (%) 11 (36.7) 19 (63.3) 0.03
 SOFA score (mean) 3.12 ± 1.9 2.83 ± 2.1 0.36
 Mechanic ventilation requirement, n (%) 1 (3.3) 1 (3.3) 0.98
Typical radiological findings, n (%) 29 (96.7) 27 (90) 0.30